Maxi Investments CY Ltd Makes New $3.75 Million Investment in Caris Life Sciences, Inc. $CAI

Maxi Investments CY Ltd purchased a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 210,670 shares of the company’s stock, valued at approximately $3,754,000. Maxi Investments CY Ltd owned 0.07% of Caris Life Sciences at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. MetLife Investment Management LLC boosted its position in shares of Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after acquiring an additional 755 shares during the period. Global Retirement Partners LLC increased its holdings in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after buying an additional 999 shares during the period. Sterling Capital Management LLC boosted its position in shares of Caris Life Sciences by 128.3% during the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock worth $34,000 after acquiring an additional 1,083 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Caris Life Sciences by 839.4% during the first quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock valued at $29,000 after purchasing an additional 1,469 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in shares of Caris Life Sciences by 15.0% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 11,932 shares of the company’s stock valued at $322,000 after purchasing an additional 1,560 shares during the last quarter.

Caris Life Sciences Stock Performance

NASDAQ CAI opened at $26.27 on Monday. The company has a market capitalization of $7.42 billion, a price-to-earnings ratio of 72.97 and a beta of 0.68. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66. Caris Life Sciences, Inc. has a twelve month low of $14.19 and a twelve month high of $42.50. The stock has a fifty day simple moving average of $18.43 and a 200 day simple moving average of $18.54.

Caris Life Sciences declared that its Board of Directors has initiated a share buyback program on Monday, June 8th that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the company to purchase up to 2.1% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Wolfe Research cut Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. BTIG Research raised their target price on shares of Caris Life Sciences from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings upgraded Caris Life Sciences from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday. Citigroup reduced their price objective on Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Wall Street Zen raised Caris Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $26.33.

Caris Life Sciences Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.